Piperazine Cyclic Urea RIP1 Inhibitors With Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors of RIP1 kinase activity, such as Necrostatin-1, lack metabolic stability and are not optimized for therapeutic applications, particularly in inhibiting necroptosis and ferroptosis, which are implicated in various pathological conditions.
Innovation Solution
Development of novel piperazine cyclic urea compounds that act as inhibitors of RIP1 kinase, exhibiting exceptional metabolic stability and being hydrolyzed in the gut or blood to yield active inhibitors, with specific substituents enhancing their efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current inhibitors of RIP1 kinase activity (such as Necrostatin-1) are used, then necroptosis and ferroptosis can be inhibited, but metabolic stability is insufficient
Solution Approach 1:
The patent modifies the chemical structure of RIP1 kinase inhibitors by introducing specific substituents (R1, R2, R3 groups with various heteroatoms and functional groups) to improve metabolic stability while maintaining inhibitory efficacy. The structural modifications include adding electron-withdrawing groups, heterocyclic rings, and specific substitution patterns that enhance resistance to metabolic degradation.
Solution Approach 2:
The invention creates composite molecular structures combining multiple functional groups (urea, cyclic structures, heteroaromatic rings, and various substituents) to achieve both high inhibitory activity and improved metabolic stability. The composite nature of these molecules allows simultaneous optimization of target binding and metabolic resistance.
2Stability of the object's composition
If novel piperazine cyclic urea compounds are developed, then metabolic stability is improved, but structural complexity increases
Solution Approach 1:
The complex molecular structure is divided into distinct functional segments: a core piperazine cyclic urea structure, heteroaryl substituents (R1, R2, R3), and various functional groups. This segmentation allows systematic optimization of each component's contribution to stability and activity, making the complex structure manageable and designable.
Solution Approach 2:
The piperazine cyclic urea core structure serves multiple functions: it provides the necessary binding interactions with RIP1 kinase, offers a scaffold for metabolic stability, and allows diverse substituent attachment points. This multi-functionality reduces overall molecular complexity by consolidating multiple roles into a single core structure.
Data Source
AI summary
Provided are piperazine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), pharmaceutically acceptable salts, hydrates and stereoisomers thereof. Provided are also pharmaceutical compositions, methods of making, and methods of use which include treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.